US 12,405,266 B2
Method for determining the number of antibodies on exosomes using quality control according to a first method of design recognition and according to a second method of electrophoresis
Hanno Wachernig, Diessen a. A. (DE)
Assigned to PARTICLE METRIX GMBH, Inning am Ammersee (DE)
Appl. No. 17/607,988
Filed by PARTICLE METRIX GMBH, Inning am Ammersee (DE)
PCT Filed Apr. 27, 2020, PCT No. PCT/DE2020/000083
§ 371(c)(1), (2) Date Nov. 1, 2021,
PCT Pub. No. WO2020/221382, PCT Pub. Date Nov. 5, 2020.
Claims priority of application No. 10 2019 003 132.6 (DE), filed on May 2, 2019.
Prior Publication US 2022/0341917 A1, Oct. 27, 2022
Int. Cl. G01N 33/50 (2006.01); G01N 21/64 (2006.01); G01N 33/53 (2006.01)
CPC G01N 33/5076 (2013.01) [G01N 21/6456 (2013.01); G01N 33/5308 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method for determining the fluorescence and the number of antibodies on exosomes using a measurement quality control, comprising the following features:
a) for preparation for a measurement, filling a measurement cell (10) with a solution composed of fluorescent antibodies and exosomes as sample (9),
b) performing a first measurement with a nanoparticle tracking measurement arrangement including a combination of lasers and filters for irradiation of the measurement cell (10) in vitro with rapid changeover and an optical device (15) for imaging thereof,
c) analyzing images detected by the optical device (15) in the first measurement for detecting the fluorescence and a number of antibodies by nanoparticle tracking analysis,
d) performing a first comparative measurement by video pattern recognition using the sample, the measurement cell, and the nanoparticle tracking measurement arrangement as used in the first measurement of step b), wherein pattern differences between exosomes without antibody conjugation and those with antibody conjugation are detected, and
e) performing a video pattern recognition analysis for said first comparative measurement for detecting the number of antibodies, and comparing the number of antibodies detected in the first measurement of step b) with the number of antibodies detected in the first comparative measurement for quality control.